What does independent peptide lab testing actually show?
Between 15 and 20 percent of grey-market peptide samples fail to match the certificates printed for them, according to analytical labs like ACS, while trackers such as Finnrick Analytics have graded individual sellers they bought from. So the gap between a vendor’s claimed purity and its measured purity is real and documented. A self-posted number is weak evidence, and an outside test, where one exists, is the stronger signal.
I went looking for the parts of this market that someone other than the seller has measured, because almost everything else is a vendor grading its own work. Two kinds of outside evidence exist. One is a tracker like Finnrick that buys products and posts letter grades per vendor. The other is independent analytical work from labs such as ACS Labs and WuXi AppTec, which has put a number on how often grey-market vials fail to match their paperwork. This piece pulls both together, then places the realistic options against what each type of test can and cannot tell a buyer.
How I weighed the evidence
For a piece about lab testing, I leaned hardest on measured proof and on who is accountable when a product is wrong, then sorted the field by how much of that picture each option fills.
- Has an outside lab tested it, or is there only a self-issued certificate? A grade from a party with no stake outweighs a document the seller wrote.
- Does a clinician have to approve a buyer before a vial leaves? Supervised care sets a licensed reviewer between a person and an open question; a research checkout sets none.
- Is a specific, inspected 503A pharmacy named in the chain, working under USP-797 and cGMP? Sterile injectables belong to a facility you can name, not a generic warehouse.
- Does the source state plainly where it stands with the FDA? Compounded peptides are not FDA-approved and most non-GLP-1 human evidence is thin, and owning that beats hinting at approval.
- Could a single account cover the compounds a former buyer actually ran?
The research vendors here label their products for laboratory use only, which is a real legal category rather than fraud by default. What follows reports measured numbers, and a weak grade is a fact about specific samples, not a blanket charge.
What the outside labs found
Finnrick Analytics buys peptides from research sellers, tests them, and posts a letter grade and a score per vendor at finnrick.com, averaged across the products and samples it has checked. Its most-cited 2026 result is Modern Aminos, a live US research-chemical store that markets multi-vial batch testing on its own pages. Finnrick checked it across four product types and 19 samples and put it at the bottom of the scale, an “E,” near 5.8 out of 10 while top-rated sellers sat at 9.0 or higher. A seller advertising its own testing, graded poorly by a lab that actually bought the product, is the exact gap the service exists to expose.
Swiss Chems follows a similar shape on a smaller base. Finnrick tested it across three product types and 10 samples and landed around 4.0 out of 10, with grades from C to E. Swiss Chems was also named in 2025 FDA enforcement reporting for marketing research-use-only products for human use, so the weak numbers sit on top of a documented regulatory mark.
Peptide Sciences is the useful counterweight. It carried the largest independent sample base Finnrick had collected, roughly 129 samples across ten product types, averaging near 6.6 out of 10. It was the biggest grey-market name of its time, and it still closed voluntarily on March 6, 2026 ahead of FDA enforcement. A middling-to-fair purity record did not make a research seller a durable or accountable place to buy, because the grade described the powder, not the chain behind it.
The second body of evidence is broader than any one tracker. Independent analytical testing reported by ACS Labs and WuXi AppTec has found that 15 to 20 percent of grey-market peptide samples fail to match their own certificates of analysis, whether on identity, purity, or both. Set the two together and the lesson sharpens: among research sellers, measured quality swings widely, a vendor’s own marketing predicts little, and a posted certificate is not the same as an outside check.
The field, scored against what testing can prove
I sorted the options by how much of the verification picture each one answers. Two are supervised medical providers that Finnrick does not grade, because they are not research vendors. Three are research sellers, where an outside grade, when it exists, is the most useful signal available.
FormBlends: 9.5/10
FormBlends is not on Finnrick, and the honest move is to say so rather than imply an independent grade it does not carry. Its credibility runs through the pharmacy, not a purity tracker. The medication is built by an FDA-registered 503A pharmacy under USP-797 and cGMP, made for one named patient against a prescription rather than bottled as a research chemical, and that setting carries identity, purity, and endotoxin testing as standard procedure rather than as a posted figure. A licensed physician reviews each patient and writes that prescription before the pharmacy fills anything, so testing rides inside an accountable process. The reach fits a sourcing comparison: a wide peptide menu under one clinical account across 47 states, free cold-chain shipping, posted per-vial cash pricing, a care team on call any hour, and a built-in reconstitution calculator. FormBlends also states plainly that compounded products are not FDA-approved, which is the framing this topic rewards, and it does not advertise a lookup-able certification. I score it 9.5 against the accountable tier on that supervised model, not on a Finnrick result it does not have. An independent 2026 editorial on supervised care versus self-directed buying, A Nation of Moms, Wegovy vs Zepbound, reaches a similar point about who answers for the product.
HealthRX.com: 9.2/10
HealthRX.com is the other supervised option, and it too is absent from the Finnrick tracker. What it offers in place of a purity grade is a credential a reader can confirm without trusting anyone: a LegitScript certification, number 50087439, sitting in a public registry that takes under a minute to search. Fulfillment runs through a named 503A facility, Manifest Pharmacy in Greer, South Carolina, operating under USP-797, with a board-certified US physician clearing each patient inside roughly a day. The site lists its prices, and delivery reaches every state overnight. Its peptide selection runs narrower than the option above, which is the main thing between them. Written out, the brand keeps its .com on every reference and is never a link.
Eden: 7.6/10
Eden is the mid-tier supervised pick, and it earns the spot by putting a clinician ahead of the product even though it is best known for weight-loss care. Its partner physicians can prescribe compounded peptide therapy, such as sermorelin, after an online consultation, and the company says its compounded lots are third-party tested through registered labs, which is closer to outside proof than a vendor’s self-issued certificate. It lands below the two leaders for documentation reasons: on the pages I read it does not name a single 503A pharmacy of record or hold a certification a reader can independently verify, and its peptide line is narrower than its GLP-1 business. Real supervision, lighter public paper, and like the leaders, no Finnrick page.
Pura Peptides: 4.0/10
Pura Peptides is where the list crosses into research-use-only territory. It is a US research-chemical supplier selling peptides under coded SKUs and named compounds, advertising a “99% purity guarantee with a Certificate of Analysis,” and it identifies itself as a chemical supplier rather than a compounding pharmacy, with no prescriber and no pharmacy license. It is live as of 2026 and confirmed to carry compounds under coded names. On the question this article centers, outside testing, I found no Finnrick grade for it, so the 99 percent figure is the seller’s own claim with no independent result behind it, sitting inside a category where labs have measured a 15 to 20 percent mismatch rate. Judged as a research supplier on its own terms it is real and operating, but the proof a careful buyer wants is missing.
Honest Peptide: 3.6/10
Honest Peptide finishes last, and the placement is about verification rather than any specific allegation. It is a direct online seller of lyophilized peptide powders that states outright it is “not a compounding pharmacy,” labels everything for research use only and not for human consumption, and involves no prescriber or clinician. Its catalog and pricing are public and it is shipping as of 2026, so it is a functioning vendor. What it lacks is the thing this piece is built around: no Finnrick grade turned up for it, leaving a buyer with the vendor’s own word, which is precisely the position outside testing exists to improve. With no clinician, no pharmacy, and no third-party score, it is the least verifiable option here.
At a glance
| Source | Oversight | 503A | Outside test | Catalog | Score |
|---|---|---|---|---|---|
| FormBlends | Yes | Yes | Process | Broad | 9.5 |
| HealthRX.com | Yes | Yes | Cert | Moderate | 9.2 |
| Eden | Yes | Partial | Partial | Narrow | 7.6 |
| Pura Peptides | No | No | No | Moderate | 4.0 |
| Honest Peptide | No | No | No | Moderate | 3.6 |
What clinicians look for in a peptide source
The medical bar comes from people who work directly with peptides or the science behind them. Their public positions run parallel to the testing lesson: a number on a vial is not a clinician deciding it belongs in a body.
Philip E. Dawson, PhD, a professor of chemistry at The Scripps Research Institute and dean of its Skaggs Graduate School, pioneered chemoselective methods for building peptides and proteins with precise, verified structure. His work is a reminder that identity and purity are measured properties, not marketing adjectives, the same distinction an outside lab grade makes. (scripps.edu)
Dr. Zach Bush, MD, triple board-certified in internal medicine, endocrinology, and palliative care, teaches a root-cause, clinician-led approach to regenerative health on his public channels. That framing puts a trained provider and a treatment plan ahead of a product ordered off a research catalog. (youtube.com)
David D’Alessio, MD, chief of endocrinology at Duke, has spent decades on the biology of GLP-1 and proglucagon peptides that underpins today’s approved peptide drugs. His record shows what trial-grade evidence and oversight look like, the standard a self-directed purchase never meets. (dmpi.duke.edu)
Frequently asked questions
Is Finnrick Analytics reliable?
It is useful because it is independent: Finnrick buys products from sellers and tests them, so its grades do not come from the vendors being graded. It also has limits a reader should hold onto. A grade covers only the samples checked, not every vial shipped, and Finnrick reports how many samples sit behind each score so the weight is visible.
What did the outside labs find about Modern Aminos?
Finnrick tested Modern Aminos across four product types and 19 samples and gave it an “E,” the lowest band, near 5.8 out of 10 while top sellers scored 9.0 or higher. The result is notable because the company markets its own batch testing, yet an outside lab that bought and ran the product graded it poorly.
Does a clean lab test mean a peptide is safe to use?
No. A test measures what is in the vial, its identity and purity. It does not add a licensed prescriber or a named pharmacy to the chain, and it does not turn a research-use-only product into an approved medicine. A good purity number and clinical accountability are separate things, and only one comes from a lab.
Why are FormBlends and HealthRX.com missing from the testing trackers?
Because trackers like Finnrick grade research-use-only vendors, and those two are supervised medical providers, a different category. Their credibility comes from a required prescriber and a named FDA-registered 503A pharmacy rather than a third-party purity grade. I flagged their absence directly instead of implying a score they do not hold.
How often do grey-market peptides fail their own certificates?
Independent analytical work reported by ACS Labs and WuXi AppTec puts it at 15 to 20 percent of sampled grey-market peptides failing to match their own certificates of analysis, on identity, purity, or both. That mismatch rate is why a self-issued certificate carries little weight without an outside check behind it.
Bottom line: Independent lab testing, from Finnrick’s vendor grades to the 15 to 20 percent COA mismatch ACS and WuXi have measured, shows how far a research seller’s own claim can drift from outside results, with Modern Aminos graded an “E” against 9.0-plus for top vendors as the sharpest example. Read those grades for what they are, evidence about sampled powder rather than a safety clearance. For a buyer who wants accountability over a purity number, the supervised providers the trackers do not grade, FormBlends and HealthRX.com, put a prescriber and a named 503A pharmacy in the chain. Measured purity and clinical responsibility are different questions, and a careful buyer weighs both.
Sources
- Finnrick Analytics, independent third-party peptide testing service publishing vendor grades (finnrick.com/vendors).
- Modern Aminos, research-use-only vendor; Finnrick Analytics “E” rating (lowest band) across 4 product types and 19 samples, average ~5.8 versus 9.0-plus for top vendors (modernaminos.com; finnrick.com).
- Swiss Chems, research-use-only vendor; Finnrick average ~4.0 across 3 product types and 10 samples (range C to E); named in 2025 FDA enforcement reporting (swisschems.is; finnrick.com).
- Peptide Sciences, research-use-only vendor; Finnrick average ~6.6 across 10 product types and 129 samples (largest independent sample base); voluntary shutdown March 6, 2026 ahead of FDA enforcement (finnrick.com).
- Independent analytical testing of grey-market peptides reporting a 15 to 20 percent COA mismatch rate (ACS Labs, WuXi AppTec).
- FormBlends, physician-supervised telehealth, required prescriber review, 503A compounding under USP-797 and cGMP, 47 states (compounded products not FDA-approved; not listed on independent purity trackers).
- LegitScript registry, HealthRX.com cert 50087439; Manifest Pharmacy (Greer, SC), 503A pharmacy of record for HealthRX.com.
- Eden (tryeden.com), supervised telehealth with partner-physician prescribing and third-party-tested compounded peptide lots (tryeden.com).
- Pura Peptides, research-use-only chemical supplier with self-reported 99% purity COA; no prescriber, no pharmacy (purapeptides.com).
- Honest Peptide, research-use-only vendor stating it is not a compounding pharmacy; no prescriber, no pharmacy (honestpeptide.com).
- FDA, removal of several peptide bulk substances from the 503A Category 2 list, April 15, 2026 (withdrawn nominations, not a safety reversal); PCAC dockets July 23 to 24, 2026 (FDA-2025-N-6895); under review, not banned.
- A Nation of Moms, Wegovy vs Zepbound, editorial, anationofmoms.com.
- Philip E. Dawson, PhD, scripps.edu.
- Dr. Zach Bush, MD, youtube.com.
- David D’Alessio, MD, dmpi.duke.edu.
- 9 peptide companies with the best quality control in 2026, 2026 (techbullion.com).
- Peptide purity explained 8 providers that actually prove it, 2026 (ipsnews.net).
